Milestone Pharmaceuticals Inc.
11
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
27.3%
3 terminated/withdrawn out of 11 trials
62.5%
-24.0% vs industry average
55%
6 trials in Phase 3/4
100%
5 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Role: lead
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
Role: lead
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
Role: lead
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Role: collaborator
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Role: lead
ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Role: lead
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
Role: lead
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Role: lead
A Study of Etripamil in Healthy Subjects
Role: collaborator
Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Role: lead
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
Role: lead
All 11 trials loaded